Clorox CLX · NYSE
$86.89 +0.90% (+$0.78)
Summary
58 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 59% a year over the last 3 years.
- It earns 20 USD a year on every 100 USD of invested capital.
- It has raised its dividend 25 years in a row.
- Out of every 100 USD of revenue, 8.7 USD is left as net profit.
What to watch
- Repaying its net debt would take 5.8 years of operating profit.
- The share price is above the Bulios Fair Price.
- Revenue fell by 3.1% a year over the last 3 years.
- It pays out more in dividends than it earns: 103% of profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.9 USD for 1 USD of yearly profit. Over the last five years it was 53.9 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 1.8% a year over 5 years. Over the last 3 years it fell by 3.1% a year. For the next fiscal year analysts expect revenue to grow by 14%. Earnings per share grew by 59% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 58 USD
- Research and development 1.7 USD
- Sales and administration 16 USD
- Taxes and other 16 USD
- Net profit 8.7 USD
Net profit, industry median (Household & Personal Products) 9.2 USD
Out of every 100 USD of revenue, 8.7 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 13.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 5.73%
- Paid out of profit
- 103%
- Raised in a row
- 25 years
You receive $4.98 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 3
- Hold 20
- Sell 6
Today's price within the analysts' price targets
The average target of $91.43 is 5.2% above today's price. 10% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Health and Wellness 40%
- Household 27%
- Lifestyle 17%
- International 17%
By region
- UNITED STATES 84%
- Foreign 16%
Health and Wellness brings in 40% of revenue.
Segments in detail